Merck and Partners Real-world Evidence Research Shows Statins Fail to Lower LDL-C Threshold

Patrick Campbell of MD Magazine reports Merck, Regenstrief Institute, Indiana University School of Medicine, and the University of North Carolina Chappell Hill, found 33.7% of statin patients examined failed to reach therapeutic levels of LDL-C which should help prevent more than 1000 cardiovascular disease events.

The investigators conducted this study after noting previous studies suggesting only 20% to 64% of patients taking statins achieve a reasonably low LDL-C threshold. This time, the team involving Merck sought to discover how many patients in reality achieved the therapeutic thresholds and the impact that can influence in avoiding cardiovascular events. They conducted the retrospective, longitudinal cohort study by systematically studying electronic health record data from the Indiana Network for Patient Care (INPC).

The team analyzed 89,267 patients meeting inclusion/exclusion criteria. The investigators observed that 33.7% did not achieve the LDL-C threshold of less than 100mg per dl after 6 to 18 months. Moreover, they fond that 58% of the high-risk subgroup failed to meet a more stringent LDL-C threshold of less than 70 mg per dl.  24% of the full population and ...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee